

**Specimen Collected: 11-Mar-24 11:35**

**Ma2/Ta Antibody, IgG by Immunoblot, CSF** | **Received: 11-Mar-24 11:35** | **Report/Verified: 11-Mar-24 11:38**

Procedure	Result	Units	Reference Interval
Ma2/Ta Antibody, IgG by Immunoblot, CSF	<b>Positive * i1</b>		[Negative]

**Test Information**

i1: Ma2/Ta Antibody, IgG by Immunoblot, CSF

INTERPRETIVE INFORMATION: Ma2/Ta Antibody, IgG by Immunoblot, CSF

IgG antibodies to Ma2/Ta are associated with paraneoplastic neurologic syndromes with phenotypes most often including a combination of limbic encephalitis, diencephalic encephalitis, and brainstem encephalitis. Patients with anti-Ma2/Ta paraneoplastic neurologic syndromes should be thoroughly evaluated for cancer, including testicular cancer and adenocarcinoma, as neurologic symptoms often precede cancer diagnosis. Use of immune checkpoint inhibitors has also been associated with an increased risk of anti-Ma2 paraneoplastic neurologic disease. Consider sending testing in serum as well as CSF to improve diagnostic yield. Results (positive or negative) should be interpreted in the context of the patient's complete clinical picture, as false positives may occur and a negative result does not exclude the diagnosis of paraneoplastic neurologic disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

**Unless otherwise indicated, testing performed at:**

**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 24-071-900130

**Report Request ID:** 19127776

**Printed:** 11-Mar-24 12:37